Antengene announces ESMO 2026 poster presentations for ATG-022, ATG-037

PUBT · 2d ago
Antengene announces ESMO 2026 poster presentations for ATG-022, ATG-037
  • Antengene posted a press release on two clinical abstracts accepted for poster presentation at ESMO 2026 in Madrid, Oct. 23-27.
  • Abstracts cover Phase II results for Claudin 18.2 ADC ATG-022 in advanced gastric or gastroesophageal junction cancer.
  • Updated Phase Ib/II data for oral CD73 inhibitor ATG-037 with pembrolizumab in CPI-resistant melanoma will also be presented.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN07689) on July 20, 2026, and is solely responsible for the information contained therein.